Replies to post #4726 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

Re: ART-123 for DIC

>How much of a threat is this?<

It’s the chief competitor to GTC/Leo’s DIC program; beyond that, it’s hard to answer because Artisan does not have to show its cards to the same degree that a public company does.

What we can say is that, to date, there are more preclinical and clinical data to support the use of antithrombin to treat DIC (#msg-20150779, #msg-20150658) than there are to support the use of thrombomodulin.

In the event that both drugs make it to market with a DIC indication, I would expect ATryn to have an edge in production cost.